HIV & TB: An R & D tale of two vaccines

WEDNESDAY 27 JANUARY 2021, 18:45 – 20:15 (UTC) CHANNEL 2

Recording available to HIV r4P // Attendees now and to the public from April 1, 2021.

The HIV epidemic, entering its fourth decade, has affected 75.7 million people and led to 32.7 million deaths. Much progress has been made in developing effective treatments and improving prevention options, but the challenge of developing a safe and globally effective vaccine persists. HIV incidence has remained unchanged for over 10 years, disproportionally affecting populations in sub-Saharan Africa, with UNAIDS targets far from being reached.

Meanwhile, tuberculosis (TB) remains the leading cause of death from an infectious disease, with Africa accounting for nearly 70% of TB and 27% of TB cases among people living with HIV globally. Poor diagnostics and linkage to care, in conjunction with multidrug-resistant TB, make TB a public health crisis and health security threat.

For HIV and TB, the need for universally effective vaccines has never been more urgent as public health systems struggle with the growing cost of these epidemics and threats of new pandemics, such as COVID-19, affecting prevention and treatment. While the HIV vaccine field is still exploring multiple strategies, the TB vaccine field has found a new hope with BCG and M72/ASO1E.

Although the two epidemics affect overlapping populations and their vaccine R&D faces similar struggles, the two fields seldom interact on solving common challenges. Conversely, the SARS-Co-V2 pandemic is benefiting from decades of HIV and TB vaccine R&D with many HIV stakeholders having pivoted to COVID-19.

Co-sponsored by the Global HIV Vaccine Enterprise and the TuBerculosis Vaccine Initiative (TBVI), this satellite will examine lessons learned from each R&D journey and look to a future in which integrated research supports product development. It will explore the role of the industry, how to develop mutually beneficial academic-industry relationships, and funding structures and mechanisms that create a sustainable R&D environment.

PANEL 1: Where and how can we work together to address shared issues and hasten product development?
PANEL 2: Is an integrated approach possible for a long-term effort?
  • Bart Haynes, Director, Duke Human Vaccine Institute at Duke University.
  • Mark Hatherill, Director of South African Tuberculosis Vaccine Initiative (SATVI).
  • Alex Schmidt, Experimental Medicine Leader at the Bill & Melinda Gates Medical Research Institute.
  • Mary Marovich, Director of the Vaccine Research Program at the Division of AIDS at the National Institute of Allergy and Infectious Diseases.
  • Georgia Tomaras, Professor of Surgery, Immunology and Molecular Genetics and Microbiology at Duke University.
  • Sanjay Phogat, Vice President R&D, Head Discovery Performance unit, GSK.
  • Nina Russell, deputy director, HIV, BMGF.
  • Michael Makanga, Chief Executive Officer, EDCTP.
  • Frank Cobelens, Chair, Executive Board, AIGHD.
  • Maria Grazia Pau, Senior Director, Compound Development Team Leader for HIV vaccine programs, Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Yazdan Yazdanpanah, Directeur de l’ANRS | Maladies infectieuses émergentes.
  • Carl Dieffenbach, Director of the Division of AIDS (DAIDS).

This satellite is supported by three presentations from experts in the field.

A short and long view of the HIV vaccine pipeline.

Kundai Chinyenze, MD, MPH – IAVI.

A short and long view of the TB vaccine pipeline.

Katrin Eichelberg, MSc, PhD – NIAID, NIH, DHHS.

An overview of HIV & TB Vaccine R&D Funding.

Mike Frick – Treatment Action Group.

WP Twitter Auto Publish Powered By :